Aaron Cowley (MBA ’11) | January 2025

Cowley (MBA 2011) has been named to the inaugural Scientific Advisory Board of Nirrin Technologies, a developer of analytical tools poised to transform bioprocess analysis.

Cowley is the Chief Scientific Officer at ReciBioPharm (formerly Arranta Bio), the biologics division of ReciPharm. He spearheads the vision and execution of the continuous manufacturing platform being developed for xRNA at ReciBioPharm and is one of the founders and participating members of the MIT Center of Continuous mRNA Manufacturing.

Cowley was also the co-founder and CTO at Captozyme, and a founding member and Board Member of Oxidien Pharmaceuticals. His work on redox potentiometry and its impact on the function of enzymes both in vitro and in vivo has resulted in numerous publications, patents, grant funds and private/venture capital funding.